RT Journal Article
T1 Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines.
A1 Doello, Kevin
A1 Mesas, Cristina
A1 Quiñonero, Francisco
A1 Rama, Ana R
A1 Velez, Celia
A1 Perazzoli, Gloria
A1 Ortiz, Raul
K1 Biperiden
K1 Dextromethorphan
K1 Fingolimod
K1 Glatiramer acetate
K1 Glioblastoma
K1 Haloperidol
K1 Lacosamide
K1 Levetiracetam
K1 Levomepromazine
K1 Valproic acid
AB Glioblastoma multiforme is the most common malignant primary brain tumor in adults. Despite new treatments developed including immunomodulation using vaccines and cell therapies, mortality remains high due to the resistance mechanisms presented by these tumor cells and the function of the blood-brain barrier that prevents the entry of most drugs. In this context of searching for new glioblastoma therapies, the study of the existing drugs to treat neurological disorder is gaining great relevance. The aim of this study was to determine, through a preliminary in vitro study on human glioblastoma (A172, LN229), anaplastic glioma (SF268) and neuroblastoma (SK-N-SH) cell lines, the possible antitumor activity of the active principles of several drugs (levomepromazine, haloperidol, lacosamide, valproic acid, levetiracetam, glatiramer acetate, fingolimod, biperiden and dextromethorphan) with the ability to cross the blood-brain barrier and that are commonly used in neurological disorders. Results showed that levetiracetam, valproic acid, and haloperidol were able to induce a relevant synergistic antitumor effect when associated with the chemotherapy currently used in clinic (temozolomide). Regarding the mechanism of action, haloperidol, valproic acid and levomepromazine caused cell death by apoptosis, while biperiden and dextromethorphan induced autophagy. Fingolimod appeared to have anoikis-related cell death. Thus, the assayed drugs which are able to cross the blood-brain barrier could represent a possibility to improve the treatment of neural tumors, though future in vivo studies and clinical trials will be necessary to validate it.
PB Springer New York LLC
YR 2022
FD 2022-11-09
LK http://hdl.handle.net/10668/21319
UL http://hdl.handle.net/10668/21319
LA en
NO Doello K, Mesas C, Quiñonero F, Rama AR, Vélez C, Perazzoli G, et al. Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines. Neurotox Res. 2022 Dec;40(6):1645-1652.
DS RISalud
RD Apr 20, 2025